PPARA and metabolic dysfunction-associated steatotic liver disease: The feasibility of dual- and pan-PPAR agonists in NAFLD also highlight the potential implications of these drugs in the progression of organ dysfunction caused by ectopic fat deposition in the pancreas, kidneys, and heart.